Repository of Research and Investigative Information

Repository of Research and Investigative Information

Larestan University of Medical Sciences

The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials

(2021) The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology. p. 11. ISSN 0014-2999

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM). We searched PubMed, Embase, Scopus, Web of Science (WOS), and Cochrane Library databases to identify all the randomized clinical trials (RCTs) up to August 23, 2020. Heterogeneity of the included studies was evaluated using Cochrane's Q test and the I-2 statistic. Moreover, a random-effects model was used to pool the weighted mean differences (WMDs) and their 95 confidence intervals (CIs). Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected. GLP-1RAs intake significantly reduced body mass index (BMI) (WMD -1.57, 95CI; -2.74, -0.39), waist-circumference (WC) (WMD -4.14, 95CI; -7.09, -1.19), body weight (WMD -4.20, 95CI; -8.15, -0.25) among the body mass indices. Additionally, GLP-1RAs leads to lower postprandial plasma glucose (PPG) levels (WMD -25.73 mg/dl, 95CI; -32.71, -18.75). We also found that GLP-1RAs intake has no significant effect on the waist-hip ratio (WHR) (WMD -0.01, 95CI; -0.03, 0.02), fasting blood glucose (FBG) (WMD -2.12 mg/dl, 95CI; -6.23, 1.96), hemoglobin Al c (HbA1c) (WMD -0.08, 95CI; -0.21, 0.04), and homeostatic model assessment for insulin resistance (HOMA-IR) levels (WMD -0.31, 95CI; -0.69, 0.07). GLP-1RAs therapy showed a greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, and HbAl c compared with other therapies in patients with T2DM and NAFLD.

Item Type: Article
Keywords: Glucagon-like peptide-1 receptor agonist Type 2 diabetes mellitus Non-alcoholic fatty liver disease Liraglutide Exenatide weight-gain hepatic steatosis exenatide obesity glp-1 liraglutide biology Pharmacology & Pharmacy
Divisions: Education Vice-Chancellor Department > Faculty of Medicine > Department of Basic Science > Department of Nutrition
Page Range: p. 11
Journal or Publication Title: European Journal of Pharmacology
Journal Index: ISI
Volume: 893
Identification Number: https://doi.org/10.1016/j.ejphar.2020.173823
ISSN: 0014-2999
Depositing User: خانم موهبت شیوخی
URI: http://eprints.larums.ac.ir/id/eprint/334

Actions (login required)

View Item View Item